Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Carcinoma, Ductal × talimogene laherparepvec × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 3 Triple Negative Breast Neoplasms 1 Pleural Effusion, Malignant 1 Neoplasm Metastasis 1 Melanoma 1 Lung Neoplasms 1 Carcinoma, Hepatocellular 1 Carcinoma, Ductal, Breast 1 Carcinoma, Ductal 1 Breast Neoplasms 1

Interventions

talimogene laherparepvec 1 Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02779855 2026-03-10

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed

50 enrolled 12 charts

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡